Cipla Partners with Qilu to Bring Pembrolizumab Biosimilar to US Market
Cipla and Qilu Pharmaceutical partner to commercialise QL2107, a pembrolizumab biosimilar, in the US, strengthening Cipla’s oncology and biosimilars portfolio.
Achin Gupta | 04/09/2026 | By News Bureau | 100
Cipla Partners with CTTQ to Develop and Commercialise HER2-Targeted ADC in Emerging Markets
Cipla and CTTQ partner to expand access to TQB2102, an investigational HER2 bispecific ADC being evaluated across HER2-expressing cancers.
Achin Gupta | 01/09/2026 | By News Bureau | 109
Cipla Wins US FDA Approval for Generic Advair Diskus
Cipla has received US Food and Drug Administration (FDA) approval for its generic Advair Diskus (fluticasone propionate and salmeterol inhalation powder) in all 3 strengths.
Achin Gupta | 29/07/2026 | By News Bureau | 128
Cipla Launches Saxenda for Weight Management
Cipla has strengthened its US portfolio with the launch of a generic version of Saxenda (liraglutide injection), indicated for chronic weight management. The launch follows ANDA approval from the US Food and Drug Administration (FDA), granted to its partner Orbicular, paving the way for expanded access to a more affordable GLP-1 therapy in the US.
Achin Gupta | 02/03/2026 | By News Bureau | 277
Pfizer and Cipla Form Exclusive Marketing Partnership for Select Brands in India
Pfizer and Cipla have joined forces in an exclusive marketing and distribution agreement for select brands in India. The collaboration aims to improve access and availability of these key medicines, ensuring patients across the country benefit from a wider reach and streamlined supply.
Achin Gupta | 19/12/2025 | By News Bureau | 337
Cipla Launches India's First Dedicated Lung Health Diagnostics Centre in Delhi
Cipla has opened the country’s first dedicated lung diagnostics centre in Delhi, equipped to conduct over 60 tests across respiratory function, microbial studies, immune profiling, blood chemistry and imaging.
Achin Gupta | 29/11/2025 | By Dineshwori | 305
Cipla Elevates Achin Gupta as Next Managing Director and Global CEO
Cipla has announced the elevation of Achin Gupta as its next Managing Director and Global Chief Executive Officer, effective April 1, 2026. Currently serving as the company’s Global Chief Operating Officer, Gupta will take over from Umang Vohra, who will step down upon completion of his term on March 31, 2026.
Achin Gupta | 30/10/2025 | By Dineshwori | 539
Cipla launches HUENA, maiden non-antibiotic drug in India for recurring UTIs
With HUENA, Cipla becomes the first in India to offer Methenamine Hippurate, a non-antibiotic therapy for recurrent UTIs, strengthening its fight against AMR.
Achin Gupta | 06/09/2025 | By Dineshwori | 201
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy